ClinicalTrials.gov Identifier: NCT04519567 Responsible Party: Larimar Therapeutics, Inc. First Posted: August 19, 2020
A Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
Actual Study Start Date: July 31, 2020
Estimated Primary Completion Date: June 30, 2021
Estimated Study Completion Date: June 30, 2021
Thursday, August 20, 2020
Subscribe to:
Posts (Atom)
